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Summary
Background
Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity
are risk factors for development of cardiovascular disease (CVD). The aim of this study
was to investigate the effect of weight loss and weight maintenance with and without
liraglutide treatment on plasma lipid profiles and apoB.
Methods
Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m2 [mean ± SD]) were
included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants
were randomized to weight maintenance with meal replacements with or without
liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss
and after 1 year of weight maintenance were subjected to nuclear magnetic
resonance-based lipidomics analysis.
Results
After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean±SD) of their body
weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly),
including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol,
triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year
ofmaintainedweight loss, themajority of the lipids had returned to pre-weight loss levels even
though weight loss was successfully maintained in both groups. Interestingly, apoB levels
remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in
contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).
Conclusion
An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids
and the atherogenic marker apoB. After 1 year of weight maintenance, only study partic-
ipants treated with liraglutide maintained reduced levels of apoB, despite similar body
weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and
thus reflect lower CVD risk. Including apoB measurements in clinical practice when mon-
itoring patients with dislipidemia or CVD might prove to be useful.
Keywords: apoB, liraglutide, metabolomics, weight loss.
Introduction
The prevalence of obesity is increasing and contributes
significantly to the pathogenesis of cardiovascular dis-
ease (CVD) (1–3). Individuals with obesity often have an
altered composition of circulating plasma lipids (termed
dislipidemia), which includes increased levels of
apolipoprotein B (apoB), decreased levels of high-density
lipoprotein (HDL) and altered particle composition of low-
density lipoprotein (LDL) (4,5). Increased plasma levels of
apoB seem to independently serve as a risk marker for
CVD (4,6–8).
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Levels of apoB have thus been suggested to be a
superior predictor of CVD compared with levels of LDL
because of the 1:1 ratio of apoB molecules and number
of atherogenic lipoprotein particles (9–12). Measurement
of apoB levels therefore provides information about all
the atherogenic lipoproteins (very-LDL [VLDL], LDL and
IDL) whereas measurement of only LDL levels does not
account for VLDL and IDL levels. Individuals with obesity,
metabolic syndrome and/or type 2 diabetes (T2D) fre-
quently have increased levels of apoB despite relatively
more normal LDL concentrations (13,14). Furthermore,
these patient groups also have a two-fold to fourfold in-
creased risk of CVD (15–17). An increased concentration
of apoB and thus an increased amount of apoB-
containing lipoproteins (VLDL, IDL and LDL) may trigger
the process of atherosclerosis (10). Additionally, elevated
levels of apoB have been linked with structural vascular
changes including enlarged carotid intima-media thick-
ness and increased arterial stiffness (18), all of which are
risk factors of cardiovascular morbidity and mortality (18).
The glucagon-like peptide-1 receptor agonist (GLP-1RA)
liraglutide, used in the treatment of T2D (19,20), has been
approved for weight loss management in individuals with
obesity (21) as it, together with low-calorie diet, induces a
metabolically relevant sustained weight loss (~8–10 kg)
by inhibiting appetite (22,23). Furthermore, treatment with
liraglutide decreases cardiovascular mortality in individ-
uals with T2D (the recent published LEADER study (26));
however, the underlying mechanism remains unknown.
Interestingly, GLP-1 has been suggested to act as a reg-
ulator of intestinal lipid absorption through downregulation
of apoB48 (24–26), but neither the effect of long-term
GLP-1RA treatment on lipid metabolism nor its effect on
the plasma levels of apoB in weight-reduced non-diabetic
individuals with obesity have been evaluated.
Thus, we hypothesized that liraglutide may improve the
atherogenic risk profile by reducing plasma concentra-
tions of apoB. To test this, we used a nuclear magnetic
resonance (NMR) spectroscopy-based metabolomics to
delineate the potential effects of liraglutide on lipid frac-
tions in humans using plasma samples from a previous
randomized controlled clinical trial of 58 non-diabetic in-
dividuals with obesity (27). This investigation may thus
aid to the understanding of one of the mechanisms
behind the reduced risk of CVD with GLP-1RA treatment
observed with liraglutide (28).
Method
Study participants
Fifty-eight glucose-tolerant individuals with obesity were
enrolled in this previously described randomized controlled
trial (27). Participants were aged between 18 and 65 years
(45.9 ± 1.5 years) and had a mean body mass index of
34.4 kg/m2 (range 30.0–39.9 kg/m2). Individuals were ex-
cluded from entering the study if they suffered from any
acute or chronic diseases. Fifty-two participants com-
pleted the 8-week weight loss intervention period, and
42 individuals completed the 1-year study period (22 par-
ticipants in the liraglutide group and 20 participants in the
control group).
Weight loss programme
All participants were initially enrolled in a weight loss in-
tervention programme for 8 weeks with the objective to
lose of at least 7.5% body weight. Intake of calories was
based on a powdered formula mixture, which provided
810 kilocalories (3,402 kJ) per day. All products were
provided by the Cambridge Diet (Cambridge Weight
Plan). Standard recommendations for intake of essential
amino acids, fatty acids, vitamins and minerals were met
with this diet. Daily intake of protein was at least 43.2 g,
and intake of essential fatty acids and linoleic acid was
3.0 and 0.4 g, respectively.
Randomization and weight maintenance
programme
After 8 weeks on the low-calorie diet, the participants
were randomized into two groups: one receiving a
daily subcutaneous injection of liraglutide 1.2 mg daily
(Flexpen device, Victoza, Novo Nordisk A/S, Bagsværd,
Denmark) and another group serving as a control group.
Both groups followed the Cambridge Weight Loss Main-
tenance Program along with calorie restriction (calorie
need subtracted by 600 kcal) for the entire study period
of one year. Furthermore, study participants received in-
dividual guidance on diet and exercise habits from a die-
tician following official Danish guidelines. If the
participants experienced weight gain during the weight
maintenance period, they were allowed to replace up to
two meals per day with Cambridge Weight Plan products
to ensure a stable weight. Both groups maintained the
weight loss achieved in the initial weight loss programme
(weight change in liraglutide group 0.49 ± 6.84 kg
[mean ± SD] and in control group 2.23 ± 7.32 kg), and
there was no significant weight difference between the
groups after 1 year. However, the control group replaced
on an average one meal per day with a low-calorie diet
meal compared with no replacements in the liraglutide
group (liraglutide group compared with control group,
minus one meal per day (95% CI=0.6 to 1), P<0.001)
as previously described (27).
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Blood samples after an overnight fasting were obtained
before weight loss (screening), at baseline (after weight
loss/randomization) and 1 year after baseline.
Metabolite quantification
Plasma samples were analysed using a high-throughput
NMR-based platform (29). Lipids and their related metab-
olites (hereof lipid particles) in blood samples obtained at
screening (before weight loss), baseline (after weight loss)
and after 1 year of weight maintenance were detected.
The high-throughput NMR platform (Nightingale Health
Ltd, Helsinki, Finland) has previously been used in various
epidemiological and genetic studies, and details of the
experimental protocols, including sample preparation
and spectroscopy, are described in references (29–33).
Statistical analyses
Statistical analyses were performed using R, version 3.1.3
(http://www.r-project.org).
All metabolites were log base 10-transformed prior to
analysis to obtain normal distribution. Changes in metab-
olite concentrations within each group were analysed
with Students Paired t tests. Changes in metabolite con-
centrations at each time point were compared between
liraglutide and control group with a general linear model
adjusted for sex, age and delta values for weight change
or with an unpaired t-test. Data are shown as mean ± SD.
To account for multiple testing, a false discovery rate
(FDR) of 5% was used. P values < 0.026 were considered
significant.
Ethics
The study was approved by the Ethical Committee in
Copenhagen (reference number: H-4-2010-134) and was
performed in accordance with the Helsinki Declaration II.
Participation in the trial was voluntary, and the partici-
pants could retract their consent to participate at any
time. ClinicalTrials.gov Identifier: NCT02094183.
Results
Clinical characteristic of the study population
The two groups were comparable in terms of gender dis-
tribution (women/men ratio: liraglutide group: 85%/15%;
control group: 92%/8%; p = 0.7), body weight (liraglutide
group: 98.6 ± 13.5 kg; controls: 96.8 ± 9.6 kg, p = 0.6) and
body fat percentage (liraglutide group: 41.4 ± 5.8; con-
trols: 42.4 ± 4.7, p = 0.5) (Table 1).
Lipid profile during weight loss intervention
The 12 kg weight loss was associated with a global shift
in the composition of plasma lipids with significant
changes in 80 out of the 124 measured lipid fractions
(Table S1). Levels of both apoB (0.98 to 0.84 mmol/L,
p = 1.8 × 104) and apoA1 (1.57 to 1.44 mmol/L,
p = 1.1 × 105) decreased significantly. Furthermore,
plasma concentration of total cholesterol (2.27 to
2.05 mmol/L, p = 1.5 × 104), ester cholesterol (3.18 to
2.76 mmol/L, p = 0.0002), free cholesterol (1.34 to
1.24 mmol/L, p = 0.02), remnant cholesterol (1.61 to
1.36 mmol/L, p = 0.0003) and plasma triglycerides (1.46
Table 1 Demographic characteristics of study population
Characteristic Screening Baseline (randomization) One year
Inclusion
N = 58
Liraglutide
group N = 22
Control group
N = 20 p-value
Liraglutide
group Control group p-value
Women 47 (81%) 17 (77%) 19 (95%) 0.19 17 (77%) 19 (95%) 0.19
Men 11 (19%) 5 (23%) 1 (5%) 0.19 5 (23%) 1 (5%) 0.19
Body weight 97.6 ± 11.8 88.1 ± 11.7 82.8 ± 7.5 0.09 87.85 ± 13.38 85.02 ± 10.4 0.45
BMI (kg m2) 34.4 ± 2.8 31.3 ± 3.2 29.1 ± 2.0 0.01 31.15 ± 4.16 29.81 ± 3.11 0.25
Waist (cm) 109.2 ± 10.2 100 ± 9.7 95.3 ± 7.3 0.09 100.15 ± 14.28 96.35 ± 10.21 0.33
Waist:Hip ratio 0.92 ± 0.08 0.89 ± 0.08 0.86 ± 0.06 0.18 0.89 ± 0.10 0.85 ± 0.07 0.14
Total body fat % 41.9 ± 5.2 39.1 ± 6.3 39.5 ± 4.8 0.82 37.98 ± 6.91 38.5 ± 5.36 0.79
Delta value weight loss
(screening to baseline
and to one year)
- 12.0 ± 3.2 12.1 ± 2.5 0.91 2.23 ± 6.97 0.50 ± 6.69 0.42
Data are expressed as n (%) or mean ± SD.
BMI, body mass index.
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to 1.10 mmol/L, p = 0.009) were significantly reduced
after the weight loss intervention. Also, significant
changes in plasma concentrations of numerous sub-
classes of LDL, VLDL and HDL particles were observed
(Figure 1A and B).
Liraglutide modifies levels of apolipoprotein B
during 1 year of weight maintenance
Lipid estimates showed an overall increasing tendency,
involving subclasses of HDL, LDL and VLDL particles.
The increase in lipid fractions were seen in both groups
(Figure 2A and B, Table S2).
All VLDL and LDL particles increased after 1 year of
weight maintenance in the control group whereas, and in
contrast to, in the liraglutide-treated group, only L-VLDL
and the content of triglycerides in S-VLDL increased (Table
S2). For HDL-related particles, the control group showed
increased plasma levels of HDL3-C, apoA1, S-, M-, L-
and XL-HDL-C levels, and in the liraglutide group, plasma
levels of HDL3-C, apoA1 and S- and M- HDL-C levels and
decreases in HDL-TG content and density were observed
(Figure 2, Table 2). In spite of an increase in HDL levels in
both groups, the liraglutide group had significantly lower
HDL3-C, S-, M- and XL-HDL levels than the control group
(Figure 2, Table S2).
Figure 1 The effect of weight loss on low-density lipoprotein (LDL), very-LDL [VLDL] and high-density lipoprotein (HDL) particles. Bars represent
the change in mean lipid concentration (error bar in SD) before weight loss (week 8) and after weight loss (week 0). (A) represents plasma lipids,
LDL and subclass particle; (B) represents VLDL subclass particle; and (C) represents HDL and subclass particle. XXL_VLDL_P is expressed in
nmol, XL_VLDL_P is expressed in μmol and multiplied by 100, L_VLDL_P is expressed in μmol and multiplied by 100, M_VLDL_P is expressed
in μmol and multiplied by 10, S_VLDL_P is expressed in μmol and multiplied by 10, XS_VLDL_P is expressed in μmol and multiplied by 10,
L_LDL_P is expressed in μmol, M_LDL_P is expressed in μmol, S_LDL_P is expressed in μmol, XL_HDL_P, L_HDL_P, M_HDL_P and S_HDL_P
were multiplied by 100. LDL-D was divided by 10. Except previously mentioned lipids, others are in mmol/L. *p < 0.026.
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Furthermore, in the control group, an increase in total
plasma cholesterol (+11%, p = 0.005), remnant choles-
terol (+8%, p = 0.04), HDL-C (total cholesterol in HDL)
(+17%, p = 0.0009), total cholines (+12%, p = 1.6x10-5),
ester cholesterol (+14%, p = 0.002), free cholesterol
(+6%, p = 0.04), apoA1 (+12%L, p = 4.9x10-6) and apoB
(+7%, p = 0.025) was observed despite maintained
weight loss. Similar results were observed in the
liraglutide group with increases in cholesterol (+9%,
p = 0.04), HDL-C (+8%, p = 0.01), total cholines (+8%,
p = 0.004), ester cholesterol (+12%, p = 0.005) and apoA1
(+6%, p = 0.01). However, levels of remnant cholesterol
(p = 0.19), free cholesterol (p = 0.99) and apoB
(p = 0.36) did not increase significantly in the liraglutide
group (Figure 2, Table S2).
Discussion
Low-calorie diet-induced weight loss resulted in a global
beneficial change in the plasma lipid profile of individuals
with obesity. Furthermore, the cardio-beneficial reductions
in apoB, LDL and triglycerides achieved by weight loss
Figure 2 (A and B) The effect of weight maintenance on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles. Bars repre-
sent mean changes (error bar in SD) in lipid concentration (52 to 0 weeks) in LDL particle and subclass. L.LDL.P, M.LDL.P and S.LDL.P
expressed in μmol/L multiplied by 1,000; M.LDL.TG expressed in mmol/L multiplied by 10. *p values for the concentration of lipid particle during
weight maintenance period at 52 weeks (calculated between 0 and 52 weeks). *p values < 0.026, **p value < 0.01. #Significant difference be-
tween liraglutide and control group at 52 weeks follow-up, p values < 0.026.
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were maintained by liraglutide treatment for 1 year. Thus,
treatment with liraglutide maintained low levels of apoB,
which may contribute to explain the reduced cardiovascu-
lar mortality reported in liraglutide-treated subjects with
T2D (28). Changes in apoB levels were related to the par-
allel changes in the atherogenic lipids: LDL, VLDL and
IDL. Despite a maintained weight loss, an overall ten-
dency of increasing lipid particles towards pre-weight
loss levels, mainly in the control group, indicating that
the effect of a weight loss on lipid particles may only be
acute and transient.
We demonstrated that individuals with obesity treated
with liraglutide after weight loss were able to sustain a
weight loss-induced lowering of apoB levels in contrast
to a control group. Interactions between GLP-1RA and
levels of apoB have also been reported by others
(24,26,34–37), but the mechanism(s) underlying the effect
of liraglutide on apoB levels has remained unknown. First,
both groups sustained a comparable weight loss (~12 kg)
during the 52-week weight maintenance phase, indicating
that the apoB-lowering effect of liraglutide is independent
of weight loss. Second, liraglutide may also directly affect
the dietary uptake of lipids from the intestine or through a
reduced hepatic production of lipids. From animal stud-
ies, it has been demonstrated that infusion of GLP-1 can
reduce the intestinal uptake of lipids (reduced levels of
apoB48) and absorption of triglycerides (35). Interestingly,
in humans, the GLP-1RA exenatide is able to reduce
levels of apoB48 (36,37). Treatment with liraglutide has,
similarly to exenatide, been linked with lower levels of
total apoB (34) and has been shown to suppress
postprandial apoB48 elevation in individuals with T2D
(24). This indicates that GLP-1RAs may mediate a reduc-
tion in intestinal uptake of fat and thereby influence the
risk of atherosclerosis and CVD.
Strengths of this study includes the ability of compar-
ing the effects of liraglutide independent of the effect on
weight as both groups successfully maintained the
weight loss for 1 year. A limitation of the current study is
that the applied NMR-based metabolomics approach
cannot differentiate between plasma levels of apoB48
(marker of intestinal fat absorption) and apoB100 (marker
of hepatic derived lipoprotein), and we can only conclude
that liraglutide affects the total pool of apoB. It would
therefore have been of interest to apply a more specific
method to analyse changes in the apoB48:apoB100 ra-
tios in subjects treated with a GLP-1RA versus placebo.
Future studies, using a more biased approach to assess
such changes in plasma levels of apoB48 and apoB100,
are therefore needed.
Plasma HDL particles are highly heterogeneous in their
physiochemical properties, metabolism and biological
activity, and the HDL response is variable and affected
both by weight loss and by the type of dietary intervention
(38,39). The effect of liraglutide on HDL levels has previ-
ously been described by others with diverging directions
(40–44). The clinical relevance of lower HDL levels in
liraglutide-treated individuals is not completely clarified.
HDL-C is a known predictor of CVD; however, the causal
link between HDL and atherosclerosis is still uncertain
(45). In contrast, we observed lower HDL-C concentra-
tions in liraglutide-treated individuals compared with
Table 2 Biochemical measures in study population
Liraglutide Control group
Variable Inclusion Randomization One year p-value Randomization One year p-value
Serum Cholesterol (mmol/L) 4.53 ± 0.86 4.12 ± 0.58 4.42 ± 0.76 0.037 3.87 ± 0.75 4.40 ± 0.90 0.005
Triglycerides (mmol/L) 1.5 ± 0.84 1.12 ± 0.32 1.09 ± 0.44 0.395 0.99 ± 0.28 1.17 ± 0.84 0.519
VLDL-C (mmol/L) 0.90 ± 0.28 0.74 ± 0.17 0.77 ± 0.20 0.443 0.68 ± 0.17 0.76 ± 0.30 0.083
VLDL-D (nm) 36.96 ± 1.57 35.96 ± 0.85 36.20 ± 1.01 0.197 35.75 ± 0.72 36.19 ± 1.48 0.088
LDL-C (mmol/L) 1.57 ± 0.48 1.45 ± 0.33 1.57 ± 0.41 0.090 1.29 ± 0.38 1.46 ± 0.47 0.138
LDL-D (nm) 23.62 ± 0.12 23.73 ± 0.08 23.67 ± 0.07 0.0005 23.77 ± 0.10 23.67 ± 0.11 0.0004
HDL-C (mmol/L) 1.35 ± 0.28 1.25 ± 0.15 1.36 ± 0.24 0.014 1.28 ± 0.23 1.51 ± 0.32 0.0009
HDL-D (nm) 9.95 ± 0.23 9.99 ± 0.15 10.04 ± 0.21 0.170 9.98 ± 0.15 10.08 ± 0.22 0.0046
HDL2.C (mmol/L) 0.84 ± 0.27 0.77 ± 0.15 0.86 ± 0.22 0.036 0.81 ± 0.19 0.99 ± 0.29 0.073
HDL3.C (mmol/L) 0.51 ± 0.04 0.48 ± 0.03 0.50 ± 0.04 0.031 0.48 ± 0.05 0.52 ± 0.05 3.14 x 10-5
ApoA1 (g/L) 1.57 ± 0.16 1.44 ± 0.10 1.53 ± 0.15 0.0096 1.44 ± 0.15 1.63 ± 0.19 4.89 x 10-6
ApoB (g/L) 0.98 ± 0.21 0.87 ± 0.15 0.89 ± 0.17 0.364 0.80 ± 0.15 0.88 ± 0.22 0.025
ApoBApoA1 0.63 ± 0.15 0.61 ± 0.10 0.59 ± 0.12 0.180 0.56 ± 0.10 0.55 ± 0.16 0.370
Data are expressed as mean ± SD. D represents diameter of particles. C represents the content of cholesterol within each lipoprotein particle. p
values are calculated by paired t tests comparing lipid levels at randomization and 1 year follow-up. False discovery rate (FDR) corrected sig-
nificance p-value < 0.02.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-LDL.
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controls as well as lower levels of HDL3-C, S- and M-HDL
particles. These change may reflect a nutrient-derived
attenuation of reverse cholesterol transportation aided
by HDL particles, but future studies are needed to clarify
this potential mechanism.
Participants in this study were obese, but otherwise
healthy and severe dyslipidemia, was not registered in this
population. Therefore, it can be speculated that greater
changes in lipid profiles, including levels of apoB, may
be found in populations with more severe degrees of
dislipidemia or known CVD. LDL cholesterol is routinely
measured in clinical practice, but as mentioned, LDL
measurements have certain disadvantages. The LDL
cholesterol concentration does not contain information
on other atherogenic lipoproteins, and some patients will
develop atherosclerotic disease despite LDL within the
normal range (46). Hence, it might be clinically relevant
to include measurements of apoB when monitoring
patients with dislipidemia and CVD to provide a more ac-
curate lipid profile for risk development of a CVD event.
In conclusion, acute weight loss in individuals with
obesity improves the atherogenic lipid profiles, but the
changes revert towards screening levels despite weight
maintenance. However, with liraglutide treatment, the
lowering of apoB levels is maintained, reflecting a change
in LDL metabolism, which may contribute to a decreased
CVD risk.
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